paper_id,claim,figure_id,title,caption,local_image_path,url
PMC8609493,A methods flowchart is available as online supplemental figure 1.,PMC8609493_figure_1,Figure 1.,"Flow chart for trial inclusion. ICTRP, International Clinical Trials Registry Platform.",./data/PMC8609493/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/bd306c385117/bmjopen-2021-053096f01.jpg
PMC8609493,Details of all exclusions are available in figure 1.,PMC8609493_figure_1,Figure 1.,"Flow chart for trial inclusion. ICTRP, International Clinical Trials Registry Platform.",./data/PMC8609493/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/bd306c385117/bmjopen-2021-053096f01.jpg
PMC8609493,Figure 3 shows the reporting of results by registry.,PMC8609493_figure_3,Figure 3.,"Result reporting rate per clinical trial registry.* *The count of registrations is inclusive of known cross-registrations for included trials, therefore the denominators will sum to >285. ANZCTR, Australian New Zealand Clinical Trials Registry; ChiCTR, Chinese Clinical Trial Registry; CRiS, Clinical Research Information Service (South Korea); CTRI, Clinical Trials Registry—India; EudraCT, European Union Drug Regulation Authorities Clinical Trials Database; IRCT, Iranian Registry of Clinical Trials; JapicCTR, Japan Pharmaceutical Information Center Clinical Trial Registry; PACTR, Pan African Clinical Trial Registry; RPCEC, Cuban Public Registry of Clinical Trials; SLCTR, Sri Lanka Clinical Trials Registry; UMIN-CTR, University Hospital, Medical Information Network Clinical Trial Registry.",./data/PMC8609493/images/figure_3.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/247d78cd948b/bmjopen-2021-053096f03.jpg
PMC8609493,"Open in a new tab
COVID-19 clinical trial results by dissemination route.Figure 3.",PMC8609493_figure_3,Figure 3.,"Result reporting rate per clinical trial registry.* *The count of registrations is inclusive of known cross-registrations for included trials, therefore the denominators will sum to >285. ANZCTR, Australian New Zealand Clinical Trials Registry; ChiCTR, Chinese Clinical Trial Registry; CRiS, Clinical Research Information Service (South Korea); CTRI, Clinical Trials Registry—India; EudraCT, European Union Drug Regulation Authorities Clinical Trials Database; IRCT, Iranian Registry of Clinical Trials; JapicCTR, Japan Pharmaceutical Information Center Clinical Trial Registry; PACTR, Pan African Clinical Trial Registry; RPCEC, Cuban Public Registry of Clinical Trials; SLCTR, Sri Lanka Clinical Trials Registry; UMIN-CTR, University Hospital, Medical Information Network Clinical Trial Registry.",./data/PMC8609493/images/figure_3.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/247d78cd948b/bmjopen-2021-053096f03.jpg
PMC8609493,"ANZCTR, Australian New Zealand Clinical Trials Registry; ChiCTR, Chinese Clinical Trial Registry; CRiS, Clinical Research Information Service (South Korea); CTRI, Clinical Trials Registry—India; EudraCT, European Union Drug Regulation Authorities Clinical Trials Database; IRCT, Iranian Registry of Clinical Trials; JapicCTR, Japan Pharmaceutical Information Center Clinical Trial Registry; PACTR, Pan African Clinical Trial Registry; RPCEC, Cuban Public Registry of Clinical Trials; SLCTR, Sri Lanka Clinical Trials Registry; UMIN-CTR, University Hospital, Medical Information Network Clinical Trial Registry.Figure 4A–C shows cumulative incidence plots for time-to-publication and 95% CIs.",PMC8609493_figure_4,Figure 4.,(A–C) Time to results across dissemination routes.,./data/PMC8609493/images/figure_4.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/15caa2086329/bmjopen-2021-053096f04.jpg
PMC8609493,Figure 5 includes a cumulative incidence plot for any results with expanded follow-up time.,PMC8609493_figure_5,Figure 5.,Time to results dissemination from registered completion date—extended follow-up.,./data/PMC8609493/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/dcec337bcf98/bmjopen-2021-053096f05.jpg
PMC8609493,Figure 4A–C shows cumulative incidence plots for time-to-publication and 95% CIs.,PMC8609493_figure_4,Figure 4.,(A–C) Time to results across dissemination routes.,./data/PMC8609493/images/figure_4.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/8609493/15caa2086329/bmjopen-2021-053096f04.jpg
